Renovaro Biosciences Announces Results of Special Meeting of Shareholders
26 January 2024 - 4:45AM
Renovaro Biosciences Inc. (NASDAQ: RENB) (the “Company”), a
biotechnology corporation focusing on cell, gene, and
immunotherapy, announced today the results of the Company’s Special
Meeting of Shareholders held at 12:00 pm ET on January 25, 2024.
All of the matters put forward before the Company's shareholders
for consideration and approval, as set out in the Company's
definitive proxy statement dated January 3, 2024, were
approved by the requisite number of votes cast at the meeting.
For complete results on all matters voted on at the meeting,
please consult the Company's Form 8-K which will be filed on EDGAR
at www.sec.gov/edgar.
ABOUT THE COMPANYRenovaro has developed
advanced cell, gene, and immunotherapy platforms designed to renew
the body’s natural tumor-fighting capabilities against cancer and
infectious diseases. For more information on Renovaro, go to their
website at www.renovarobio.com.
Contact: ir@renovarobio.comSource: Renovaro
Bioscience Inc.
Renovaro (NASDAQ:RENB)
Historical Stock Chart
From Apr 2024 to May 2024
Renovaro (NASDAQ:RENB)
Historical Stock Chart
From May 2023 to May 2024